Skip to main content

Malignant hematological diseases

The malignant hematological diseases section deals with all aspects of malignant hematological diseases including clinical and basic research related to topics related to lymphomas, leukemia, and myeloproliferative diseases.

  1. Even though the incidences of hematologic malignancies have received considerable attentions globally, there is paucity of information on patterns of hematologic malignancy in Eritrea. The study was conducted ...

    Authors: Natnael Belai, Amon Solomon Ghebrenegus, Amin Ata Alamin, Ghirmay Embaye and Amanuel Kidane Andegiorgish

    Citation: BMC Hematology 2019 19:8

    Content type: Research article

    Published on:

    The Correction to this article has been published in BMC Hematology 2019 19:12

  2. The BCR-ABL1 fusion gene underlying the pathogenesis of CML can arise from a variety of breakpoints. The e13a2 and e14a2 transcripts formed by breakpoints occurring around exon 13 and exon 14 of the BCR gene resp...

    Authors: Graeme Greenfield, Ross McMullan, Nuala Robson, Julie McGimpsey, Mark Catherwood and Mary Frances McMullin

    Citation: BMC Hematology 2019 19:7

    Content type: Research article

    Published on:

  3. Tumor lysis syndrome (TLS) is a life-threatening emergency disorder, caused by an abrupt release of intracellular metabolites after tumor cell death. It is characterized by a series of metabolic manifestations...

    Authors: Haileleul Micho, Yasin Mohammed, Daniel Hailu and Solomon Genet

    Citation: BMC Hematology 2018 18:22

    Content type: Research article

    Published on:

  4. Chromosomal abnormalities are diagnostic and prognostic key factors in acute myeloid leukemia (AML) patients, as they play a central role for risk stratification algorithms. High hyperdiploidy (HH), a rare cyt...

    Authors: Abdulsamad Wafa, Suher ALmedania, Abdulmunim Aljapawe, Thomas Liehr, Soulaiman E. Soulaiman, Raja Mouna, Moneeb A. K. Othman and Walid ALachkar

    Citation: BMC Hematology 2018 18:21

    Content type: Case report

    Published on:

  5. Immunophenotypic analysis of the bone marrow (BM) cells has proven to be helpful in the diagnosis of Myelodysplastic Syndromes (MDS). However, the usefulness of flow cytometry (FCM) for the detection of myelod...

    Authors: Ana Aires, Maria dos Anjos Teixeira, Catarina Lau, Cláudia Moreira, Ana Spínola, Alexandra Mota, Inês Freitas, Jorge Coutinho and Margarida Lima

    Citation: BMC Hematology 2018 18:6

    Content type: Research article

    Published on:

  6. Myelodysplastic syndromes (MDS) encompass a diverse group of hematologic disorders characterized by ineffective and malignant hematopoiesis, peripheral cytopenias and significantly increased risk of progressio...

    Authors: Rory M. Shallis and Amer M. Zeidan

    Citation: BMC Hematology 2018 18:4

    Content type: Commentary

    Published on:

  7. Since the discovery of specific histocompatibility, literature has associated genes involved in the immune response, like the Human Leucocyte Antigen (HLA), with a better prognosis in transplantation. However,...

    Authors: Daniele Kazue Sugioka, Carlos Eduardo Ibaldo Gonçalves and Maria da Graça Bicalho

    Citation: BMC Hematology 2016 16:25

    Content type: Research article

    Published on:

  8. Survival analysis is commonly used to determine the treatment effect among acute lymphoblastic leukemia (ALL) patients who undergo allogeneic stem cell transplantation (allo-SCT) or other treatments. The aim o...

    Authors: Chatree Chai-Adisaksopha, Alfonso Iorio, Christopher Hillis, Wendy Lim and Mark Crowther

    Citation: BMC Hematology 2016 16:17

    Content type: Research article

    Published on:

  9. Multiple myeloma is a plasma cell tumour with an annual incidence in the UK of approximately 40–50 per million i.e. about 4500 new cases per annum. The triple combination cyclophosphamide, bortezomib (Velcade®...

    Authors: Sarah Brown, Samantha Hinsley, Mónica Ballesteros, Sue Bourne, Paul McGarry, Debbie Sherratt, Louise Flanagan, Walter Gregory, Jamie Cavenagh, Roger Owen, Cathy Williams, Martin Kaiser, Eric Low and Kwee Yong

    Citation: BMC Hematology 2016 16:14

    Content type: Study protocol

    Published on:

  10. CC-486 is an oral formulation of the epigenetic modifier azacitidine. In an expanded phase 1 trial, CC-486 demonstrated clinical and biological activity in patients with International Prognostic Scoring System...

    Authors: Guillermo Garcia-Manero, Antonio Almeida, Aristoteles Giagounidis, Uwe Platzbecker, Regina Garcia, Maria Teresa Voso, Stephen R. Larsen, David Valcarcel, Lewis R. Silverman, Barry Skikne and Valeria Santini

    Citation: BMC Hematology 2016 16:12

    Content type: Study protocol

    Published on:

  11. Langerhans cells (LC) are bone marrow-derived cells in the skin. The LC donor/recipient chimerism is assumed to influence the incidence and severity of graft-versus-host disease (GVHD) after hematopoietic stem...

    Authors: Sabrina Peters, Christian Junghanss, Anne Knueppel, Hugo Murua Escobar, Catrin Roolf, Gudrun Knuebel, Anett Sekora, Iris Lindner, Ludwig Jonas, Mathias Freund and Sandra Lange

    Citation: BMC Hematology 2016 16:11

    Content type: Research article

    Published on:

  12. Chronic lymphocytic leukemia (CLL) is a mature B-cell neoplasm characterized by the expansion of CD5-positive lymphocytes in peripheral blood. While CLL is the most common type of leukemia in Western populatio...

    Authors: Abibatou Sall, Awa Oumar Touré, Fatimata Bintou Sall, Moussa Ndour, Seynabou Fall, Abdoulaye Sène, Blaise Félix Faye, Moussa Seck, Macoura Gadji, Tandakha Ndiaye Dièye, Claire Mathiot, Sophie Reynaud, Saliou Diop and Martine Raphaël

    Citation: BMC Hematology 2016 16:10

    Content type: Research article

    Published on:

  13. At the time of diagnosis, Multiple Myeloma is commonly associated with renal impairment. Renal tubular acidosis without overt renal insufficiency is an uncommon disease presentation of myeloma. Among tubular a...

    Authors: Chathuranga Lakmal Fonseka, Sampath Rukshani Galappaththi, Jeewandarage Dhanushka Karunarathna, Dayakshi Dushyantha Kumarihami Abeyaratne and Nirmali Tissera

    Citation: BMC Hematology 2016 16:8

    Content type: Case report

    Published on:

  14. Mast cell leukemia (MCL) is rare type of neoplasia with an incidence of 1% in a large series of 342 adult patients with systemic mastocytosis (SM). Chronic basophilic leukemia (CBL) is an extremely rare type o...

    Authors: Cavit Cehreli, Inci Alacacioglu, Ozden Piskin, Halil Ates, Ruksan Cehreli, Gizem Calibasi, Erdinc Yuksel, Sermin Ozkal and Guner H Ozsan

    Citation: BMC Hematology 2014 14:17

    Content type: Case report

    Published on: